Immune-Modulating Agents

GlycoMira has developed a new class of synthetic glycosaminoglycan therapeutics that modulate the innate immune response and have potential to address unmet medical needs in oncology and other inflammatory diseases. GlycoMira’s candidate drugs are designed to have potent anti-inflammatory properties with excellent safety and chemical stability.

Therapeutic Strategy

Most therapeutic strategies for oncology and other inflammatory diseases target key molecules involved in the late stages of disease progression and are not mechanistically based on the recent understanding of disease. As an innovative mechanism-based solution, GlycoMira’s proprietary lead asset — GM-1111 — potently inhibits innate immune receptor activation at the earliest stage of disease to mitigate further progression and ultimately result in improvements in treatment efficacy and patient outcomes.

Select Publications